Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 9/20 | 0.50 |
| ▸ | MMP9 | P14780 | 9/20 | 0.50 |
| ▸ | MMP8 | P22894 | 8/20 | 0.50 |
| ▸ | MMP13 | P45452 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542639 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL5443745 | 0.75 | MMP2 (0.70) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL14945768 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL10021371 | 0.74 | ALDH1A1 (0.43) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL11607926 | 0.74 | SMN1; SMN2 (0.57) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL14935352 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL11604698 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL10522886 | 0.70 | ADAM17 (0.72) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL17360671 | 0.68 | MMP2 (0.47) | SMN1; SMN2NPSR1MMP2MMP9MMP8 | |
| SCHEMBL17294160 | 0.68 | MMP2 (0.53) | SMN1; SMN2NPSR1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | SAIL BIOMEDICINES (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-4483870-A | α-Difluoromethyl amino acids and hypertension treating compositions thereof | MERCK & CO., INC. (US) | 1984-11-20 | — | — | US | disclosed |
| EP-0007600-B1 | ALPHA-DIFLUOROMETHYL AMINO ACIDS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1983-05-11 | — | — | EP | disclosed |
| EP-0007600-A1 | Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | DDC, DDT, DDO | SMN1; SMN2 983/4885NPSR1 3434/4885MMP2 922/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | SMN1; SMN2 983/4885NPSR1 3434/4885MMP2 922/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | SMN1; SMN2 151/4885NPSR1 2149/4885MMP2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.